相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naive and CYP17 Inhibitor-naive Patients: Follow-up from the ARADES and ARAFOR Trials
Neal D. Shore et al.
EUROPEAN UROLOGY FOCUS (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naive Prostate Cancer: Results from Extended Follow-up of the ARADES Trial
Karim Fizazi et al.
EUROPEAN UROLOGY FOCUS (2017)
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Matthew R. Smith et al.
EUROPEAN UROLOGY (2016)
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
Christophe Massard et al.
EUROPEAN UROLOGY (2016)
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Kristine M. Wadosky et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study
Mariana Reza et al.
EUROPEAN UROLOGY FOCUS (2016)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
C. Parker et al.
ANNALS OF ONCOLOGY (2015)
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials
Robert J. van Soest et al.
BMC MEDICINE (2015)
Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer and Mechanisms of Resistance
D. J. Crona et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)
Fred Saad et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2015)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Karim Fizazi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Castration-Resistant Prostate Cancer: AUA Guideline Amendment
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Therapy escape mechanisms in the malignant prostate
Frederic R. Santer et al.
SEMINARS IN CANCER BIOLOGY (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
